Env-Specific IgA from Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular Cytotoxicity

María Julia Ruiz, a Yanina Ghiglione, a Juliana Falivene, a Natalia Lauffer, a,b,c María Pía Holgado, a María Eugenia Socías, a,b,c Pedro Cahn, b,c Omar Sued, a,b,c Luis Giavedoni, d Horacio Salomón, a María Magdalena Gherardi, a Ana María Rodríguez, a,c Gabriela Turk a

Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INIBIS), Universidad de Buenos Aires-CONICET, Buenos Aires, Argentina; Fundación Huésped, Buenos Aires, Argentina; Hospital J. A. Fernández, Buenos Aires, Argentina; Department of Virology and Immunology, Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, Texas, USA

ABSTRACT

Elucidating the factors that modulate HIV-specific antibody-dependent cellular cytotoxicity (ADCC) will help in understanding its role in HIV immunity. The aim of this study was to determine whether IgA could modify the magnitude of ADCC in HIV infection, abrogating its protective role. Plasma samples from 20 HIV-positive (HIV+2) subjects enrolled during primary HIV infection (PHI), 10 chronically infected subjects (chronic), and 7 elite controllers (EC) were used. ADCC was determined by using a fluorometric ADCC assay, before and after removal of plasma IgA. Data were analyzed by using nonparametric statistics. ADCC was documented in 80% of PHI enrollment samples and in 100% of PHI 12-month, chronic, and EC samples; it peaked after acute infection, reached a plateau in chronic infection, and decreased after initiation of antiretroviral treatment (ART). Significant associations between ADCC and disease progression were found only after removal of plasma IgA from 12-month PHI samples: the magnitude of ADCC not only increased after IgA removal but also correlated with CD4+ T-cell preservation. This work provides evidence that gp120-specific IgA was capable of modifying ADCC responses during natural HIV infection for the first time and adds to similar evidence provided in other settings. Furthermore, it underscores the complexity of the ADCC phenomenon and will help in an understanding of its underlying mechanisms.

IMPORTANCE

Although the induction of ADCC-mediating antibodies in HIV-infected subjects has been extensively documented, the association of these antibodies with protection from disease progression is poorly understood. Here, we demonstrate that plasma IgA is a factor capable of modifying the magnitude of IgG-mediated ADCC in HIV infection, mitigating its beneficial effect. These results help in understanding why previous studies failed to demonstrate correlations between ADCC and disease progression, and they also contribute to the notion that an HIV vaccine should stimulate the production of ADCC-mediating IgG antibodies but not IgA.

Despite the success of antiretroviral treatment (ART), human immunodeficiency virus (HIV) still represents a major public health concern (1), and a vaccine is urgently needed. One major advance of the RV144 trial was the achievement of an estimated efficacy of 31.2% (2). Subsequent correlate analyses showed that Env-specific IgG antibodies correlated inversely with infection risk (3). Moreover, antibody-dependent cellular cytotoxicity (ADCC), broadly induced by this vaccine regimen (4), was found to be a correlate of protection in vaccinees with low levels of Env-specific IgA (3). These findings suggested that the modest protection induced by the RV144 vaccine regimen might be attributed to humoral immunity and, more specifically, to ADCC.

Besides the RV144 trial, there are many other reasons to reexamine the mechanisms of ADCC during the natural course of HIV infection. The induction of ADCC-mediating antibodies in plasma (5–11), cervicovaginal fluids (12, 13), and breast milk (14) from HIV-infected subjects has been extensively documented. However, their association with protection from disease progression is less unequivocal. Cohort studies performed with elite controllers (ECs) showed that these individuals had higher ADCC than viremic subjects (9). One early report by Baum et al. (5) established that ADCC was associated with disease progression in terms of CD4+ T-cell counts, but later, other studies on recently and chronically infected subjects failed to demonstrate definitive and conclusive associations (7, 8, 11, 15–20). More recently, passively acquired ADCC activity in infants born to HIV-infected mothers was not associated with protection but was associated with reduced mortality (21).

Many factors could have influenced the dissimilar results and precluded the drawing of definite conclusions, including the use of different models to assay ADCC, inclusion criteria to enroll
| Group and patient | Age (yr) | Infection stage | No. of days postinfection | HIV-1 RNA copies/ml plasma | Log_{10} HIV-1 RNA copies/ml plasma | Viral set point^f (log_{10} HIV-1 RNA copies/ml plasma) | CD4^+ T-cell count^e,c | CD4^+ set point^f (cells/μl) | Presence of <350 CD4 cells/μl during 1st yr^g | Treatment with HAART^h |
|-------------------|----------|----------------|--------------------------|---------------------------|-------------------------------------|-----------------------------------------------|---------------------|-------------------------|---------------------------------|-------------------|
| PHI (n = 20)      |          |                |                          |                           |                                    |                                               |                     |                         |                                 |                   |
| NP01              | M 45     | Stage V        | 60                       | 2,707                     | 3.4                                 | 3.9                                           | 902                 | 600                     | No                              | No                |
| NP02              | M 40     | Stage VI       | 60                       | 8,613                     | 3.9                                 | 4.3                                           | 851                 | 758                     | No                              | No                |
| NP03              | M 47     | Stage V        | 45                       | 112                       | 2.0                                 | 2.5                                           | 743                 | 679                     | No                              | No                |
| NP04              | M 43     | Stage V        | 45                       | 19,522                    | 4.3                                 | 4.3                                           | 525                 | 442                     | No                              | No                |
| NP05              | F 37     | Stage V        | 60                       | 9,532                     | 4.0                                 | 3.6                                           | 590                 | 587                     | No                              | No                |
| NP06              | M 32     | Stage VI       | 150                      | 256,051                   | 5.4                                 | 4.7                                           | 797                 | 943                     | No                              | No                |
| NP07              | M 33     | Stage V        | 45                       | 21,986                    | 4.3                                 | 3.3                                           | 609                 | 658                     | No                              | No                |
| NP08              | F 26     | Stage VI       | 60                       | 17,420                    | 4.2                                 | 4.1                                           | 685                 | 402                     | No                              | No                |
| NP09              | F 34     | Stage V        | 24                       | >500,000                  | >5.7                                | 4.3                                           | 603                 | 490                     | No                              | No                |
| NP10              | M 73     | Stage VI       | 120                      | 13,962                    | 4.1                                 | 4.6                                           | 577                 | 544                     | No                              | No                |
| NP11              | M 30     | Stage V        | 45                       | 455,417                   | 5.7                                 | 5.2                                           | 698                 | 685                     | No                              | No                |
| P01               | F 31     | Stage V        | 30                       | >500,000                  | >5.7                                | 5.4                                           | 374                 | 342                     | Yes                             | No                |
| P02               | F 41     | Stage VI       | 90                       | 3,662                     | 3.6                                 | 3.9                                           | 302                 | 281                     | Yes                             | No                |
| P03               | M 43     | Stage V        | 45                       | 98,684                    | 5.0                                 | 4.9                                           | 256                 | 256                     | Yes                             | No                |
| P04               | M 40     | Stage V        | 70                       | 1,147                     | 3.1                                 | 3.5                                           | 568                 | 424                     | Yes                             | No                |
| P05               | M 25     | Stage VI       | 60                       | 242,199                   | 5.4                                 |                                               | 161                 |                          | Yes                             | Yes               |
| P06               | M 36     | Stage VI       | 60                       | >500,000                  | 5.7                                 |                                               | 475                 |                          | Yes                             | Yes               |
| P07               | M 26     | Stage VI       | 60                       | >500,000                  | 5.7                                 |                                               | 446                 |                          | Yes                             | Yes               |
| P08               | M 45     | Stage V        | 60                       | >500,000                  | 5.7                                 |                                               | 259                 |                          | Yes                             | Yes               |
| P09               | F 28     | Stage VI       | 30                       | >500,000                  | 5.7                                 |                                               | 222                 |                          | Yes                             | Yes               |
| Chronic (n = 10)  |          |                |                          |                           |                                    |                                               |                     |                         |                                 |                   |
| C01               | F 21     | Chronic        |                           | 85,947                    | 4.9                                 | 25                                            |                     |                         | No                              |                   |
| C02               | M 22     | Chronic        |                           | 18,580                    | 4.2                                 |                                               | 511                 |                          | No                              |                   |
| C03               | M 49     | Chronic        |                           | 43,436                    | 4.6                                 |                                               | 479                 |                          | No                              |                   |
| C04               | M 28     | Chronic        |                           | 555                       | 2.7                                 |                                               | 555                 |                          | No                              |                   |
| C05               | M 36     | Chronic        |                           | 1,288                     | 3.1                                 |                                               | 431                 |                          | No                              |                   |
| C06               | F 27     | Chronic        |                           | 1,817                     | 3.2                                 |                                               | 689                 |                          | No                              |                   |
| C07               | M 47     | Chronic        |                           | 11,026                    | 4.0                                 |                                               | 585                 |                          | No                              |                   |
| C08               | F 38     | Chronic        |                           | 22,475                    | 4.3                                 |                                               | 143                 |                          | No                              |                   |
| C09               | F 29     | Chronic        |                           | 14,784                    | 4.3                                 |                                               | 139                 |                          | No                              |                   |
| C10               | F 24     | Chronic        |                           | 253,167                   | 5.4                                 |                                               | 5                   |                          | No                              |                   |
| EC (n = 7)        |          |                |                          |                           |                                    |                                               |                     |                         |                                 |                   |
| EC01              | M 54     | Chronic        |                           | <50                       | <1.7                                |                                               | 566                 |                          | No                              |                   |
| EC02              | F 41     | Chronic        |                           | <50                       | <1.7                                |                                               | 912                 |                          | No                              |                   |
| EC03              | M 36     | Chronic        |                           | <50                       | <1.7                                |                                               | 456                 |                          | No                              |                   |
| EC04              | F 60     | Chronic        |                           | <50                       | <1.7                                |                                               | 570                 |                          | No                              |                   |
| EC05              | F 43     | Chronic        |                           | <50                       | <1.7                                |                                               | 817                 |                          | No                              |                   |
| EC06              | M 39     | Chronic        |                           | <50                       | <1.7                                |                                               | 595                 |                          | No                              |                   |
| EC07              | F 37     | Chronic        |                           | <50                       | <1.7                                |                                               | 344                 |                          | No                              |                   |

^a PHI subjects were stratified according to Fiebig stages (31).

^b Number of days from the presumed date of infection to the date at which the enrollment sample was obtained.

^c For PHI subjects, data correspond to enrollment samples. For chronically infected and EC subjects, data correspond to samples obtained at enrollment.

^d Performed by using a Versant HIV-1 RNA 3.0 assay (Siemens). Lower and upper detection limits are 50 and 500,000 HIV RNA copies/ml, respectively (1.7 and 5.7 log_{10} HIV RNA copies/ml, respectively).

^e Flow cytometry double platform (FACSCanto; BD Biosciences).

^f Applicable only to PHI subjects who did not start highly active antiretroviral therapy during the first year postinfection (see Materials and Methods).

^g Indicates whether the CD4^+ T-cell count dropped below 350 cells/μl at any time during the first year postinfection or not, thus defining subgroups where the PHI counts were <350 and >350 cells/μl (see Materials and Methods).

^h Regarding PHI subjects, data illustrate if subjects started highly active antiretroviral therapy (HAART) during the first year postinfection. For those subjects who started highly active antiretroviral therapy, enrollment samples were obtained before treatment initiation. Data indicate whether chronically infected and EC subjects had ever been on highly active antiretroviral therapy.

^i F, female; M, male.
and were ART naive, and ECs were defined as subjects infected for >5 years who had an undetectable VL (<50 HIV RNA copies/ml plasma), were ART naive, and had no record of opportunistic and/or AIDS-related diseases. The study was reviewed and approved by the Comité de Ética Humana, Facultad de Medicina, Universidad de Buenos Aires. All participants provided written informed consent.

**PLasma VL (branched DNA) (Versant HIV-1 RNA 3.0 assay; Siemens Healthcare, United Kingdom), CD4+ T-cell count (flow cytometry double platform) (BD FACScanto; BD Biosciences, USA), cellular immune activation (HLA-DR and CD38 expression on peripheral blood mononuclear cells [PBMCs] as determined by flow cytometry [26]), and plasma soluble factors (39-plex Milliplex multi-analyte panel human cytokine/chemokine kit; Millipore, USA) were assessed as described previously (26–28).

**Samples.** Blood samples were collected and centrifuged to separate plasma. For ADCC assays, plasma was first diluted (10-fold in RPMI medium), passed through a 0.2-μm-pore-size filter, and heat inactivated (1 h at 56°C). PBMCs from one HIV-negative donor were isolated by Ficoll-Hypaque density centrifugation (Amersham, Sweden), cryopreserved, and used as effector cells in ADCC assays. Cells from the same donor were used in all assays to avoid bias from donor to donor.

**RFADCC assay.** A rapid fluorometric ADCC (RFADCC) assay was performed as described previously (29). Briefly, CEM-NK target cells (AIDS Research and Reference Reagent Program) [30] were double stained with PKH26 red fluorescent cell linker (Sigma-Aldrich, USA) and CFSE (carboxyfluorescein diacetate succinimidyl ester; Molecular Probes, USA) and were ART naive. Target cells were incubated with a recombinant gp120 protein derived from the HIV-1 BaL strain (recombinant gp120BAL, obtained from the AIDS Research and Reference Reagent Program, DADIS, NIAID). After 1 h, cells were washed and resuspended in FACScanto flow cytometer (BD Biosciences, USA), and analyzed by using FACSDiva v6.1.3 software (BD Biosciences). Target cells were initially gated on a forward-scatter (FSC)–versus-side-scatter (SSC) plot and subsequently gated on an SSC-versus-PKH26 plot. Next, a PKH26-versus-CFSE plot was generated to determine the percent target cell killing (%ADCC killing), which was calculated as the proportion of cells that remained PKH26high but that had lost the viability dye (CFSE−). Results are presented as the medians of data from experiments performed in

**MATERIALS AND METHODS**

**Study subjects.** The following study groups were enrolled (Tables 1 and 2): 8 healthy HIV-seronegative donors (HIV−), 10 chronically infected subjects (chronic) infected for >3 years, detectable viral load [VL], and ART naive, 7 ECs (infected for >5 years, undetectable VL [<50 HIV RNA copies/ml plasma], ART naive, and no record of opportunistic and/or AIDS-related diseases), and 20 subjects enrolled within 6 months from the presumed date of infection (primary HIV infection [PHI]). PHI subjects were enrolled by the Grupo Argentino de Seroconversión Study Group. Inclusion criteria, time from infection, and set point calculations were reported previously (25–27). Briefly, a PHI enrollment sample was obtained in the case of detection of HIV RNA or p24 antigen with a simultaneous negative or indeterminate Western blot assay result or a positive Western blot result with a negative test within the previous 6 months. Chronically infected individuals were defined as subjects infected for >3 years who had a detectable VL (>50 HIV RNA copies/ml plasma) and were ART naive, and ECs were defined as subjects infected for >5 years who had an undetectable VL (<50 HIV RNA copies/ml plasma), were ART naive, and had no record of opportunistic and/or AIDS-related diseases. The study was reviewed and approved by the Comité de Ética Humana, Facultad de Medicina, Universidad de Buenos Aires. All participants provided written informed consent.

**PLasma VL (branched DNA) (Versant HIV-1 RNA 3.0 assay; Siemens Healthcare, United Kingdom), CD4+ T-cell count (flow cytometry double platform) (BD FACScanto; BD Biosciences, USA), cellular immune activation (HLA-DR and CD38 expression on peripheral blood mononuclear cells [PBMCs] as determined by flow cytometry [26]), and plasma soluble factors (39-plex Milliplex multi-analyte panel human cytokine/chemokine kit; Millipore, USA) were assessed as described previously (26–28).

**Samples.** Blood samples were collected and centrifuged to separate plasma. For ADCC assays, plasma was first diluted (10-fold in RPMI medium), passed through a 0.2-μm-pore-size filter, and heat inactivated (1 h at 56°C). PBMCs from one HIV-negative donor were isolated by Ficoll-Hypaque density centrifugation (Amersham, Sweden), cryopreserved, and used as effector cells in ADCC assays. Cells from the same donor were used in all assays to avoid bias from donor to donor.

**RFADCC assay.** A rapid fluorometric ADCC (RFADCC) assay was performed as described previously (29). Briefly, CEM-NK target cells (AIDS Research and Reference Reagent Program) [30] were double stained with PKH26 red fluorescent cell linker (Sigma-Aldrich, USA) and CFSE (carboxyfluorescein diacetate succinimidyl ester; Molecular Probes, USA) and were ART naive. Target cells were incubated with a recombinant gp120 protein derived from the HIV-1 BaL strain (recombinant gp120BAL, obtained from the AIDS Research and Reference Reagent Program, DADIS, NIAID). After 1 h, cells were dispensed in U-bottom 96-well plates (5,000 cells/well) together with different dilutions of inactivated plasma, in triplicates. After 15 min at room temperature, effector cells (PBMCs thawed and rested overnight) were added at an effector-to-target cell ratio of 50:1. Plates were centrifuged and incubated for 4 h at 37°C. Cells were washed, fixed, acquired on a FACScanto flow cytometer (BD Biosciences, USA), and analyzed by using FACSDiva v6.1.3 software (BD Biosciences). Target cells were initially gated on a forward-scatter (FSC)–versus-side-scatter (SSC) plot and subsequently gated on an SSC-versus-PKH26 plot. Next, a PKH26-versus-CFSE plot was generated to determine the percent target cell killing (%ADCC killing), which was calculated as the proportion of cells that remained PKH26high but that had lost the viability dye (CFSE−). Results are presented as the medians of data from experiments performed in

**TABLE 2 Summary of clinical data corresponding to HIV+ subjects enrolled per study group**

| Group | Median no. of days postinfection (IQ range)* | Viral load** | Viral set point† (mean log_{10} HIV RNA copies/ml ± SD) | Median CD4+ T-cell count‡ (cells/μl) (IQ range) | Median CD4 set point§ (cells/μl) (IQ range) |
|-------|---------------------------------------------|-------------|-----------------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| PHI   | 60 (45–60)                                   | 60,335 (8,843–488,854) | 4.6 ± 1.07                                           | 572 (320–695)                                | 544 (402–679)                                |
| PHI>350 (n = 11) | 60 (45–60)                                   | 17,420 (6,813–256,051) | 4.2 ± 0.74                                           | 685 (590–797)                                | 600 (490–685)                                |
| PHI<350 (n = 9) | 60 (37,50–65)                                 | 242,199 (51,173–500,000) | 4.9 ± 0.9                                            | 302 (239–460)                                | 311 (262–403)                                |
| Chronic (n = 10) | 16,682 (1,685–54,064)                      | 4.1 ± 0.83                                           | 455 (110–562)                                      |                                               |                                               |
| EC (n = 7) | <50                                         | <1.7                                                 | 570 (456–817)                                      |                                               |                                               |

*a Number of days from the presumed date of infection to the date at which the enrollment sample was obtained.

*b In this group, 3 subjects initiated highly active antiretroviral therapy during the first year postinfection.

† Versant HIV-1 RNA 3.0 assay (Siemens). Lower and upper detection limits are 50 and 500,000 HIV RNA copies/ml, respectively (1.7 and 5.7 log_{10} HIV RNA copies/ml, respectively).

‡ Set points were not calculated for subjects who initiated highly active antiretroviral therapy during the first year postinfection (n = 5) (see Materials and Methods).

§ IQ, interquartile.
ELISA for Env-specific plasma IgG and IgA. The gp120-specific IgG concentration and gp120-specific IgA titers were determined by an enzyme-linked immunosorbent assay (ELISA). Ninety-six-well, flat-bottomed, half-area plates (GreinerBio-One, Germany) were coated with 25 ng/well of gp120_BAL. For gp120-specific IgG quantitation, 25 µl/well of plasma dilutions (initially 1/500 for PHI enrollment samples and 1/10,000 for the other groups) was dispensed in triplicates. A standard curve was constructed, consisting of 2-fold serial dilutions of anti-gp120 monoclonal antibody 2G12 (AIDS Research and Reference Reagent Program) followed by staining with anti-human IgG-allophycocyanin (APC).

ELISA for Env-specific plasma IgG and IgA. The gp120-specific IgG concentration and gp120-specific IgA titers were determined by an enzyme-linked immunosorbent assay (ELISA). Ninety-six-well, flat-bottomed, half-area plates (GreinerBio-One, Germany) were coated with 25 ng/well of gp120_BAL. For gp120-specific IgG quantitation, 25 µl/well of plasma dilutions (initially 1/500 for PHI enrollment samples and 1/10,000 for the other groups) was dispensed in triplicates. A standard curve was constructed, consisting of 2-fold serial dilutions of anti-gp120 monoclonal antibody 2G12 starting at 24 ng/ml. IgG detection was performed by using an anti-human IgG antibody labeled with horseradish peroxidase (HRP; Sigma-Aldrich, USA) and developed with tetramethylbenzidine (TMB)-ELISA solution (BD Biosciences, USA). The absorbance at 450 nm was read on a Multiskan EX microplate reader (Thermo/Labsystems). The IgG concentration was extrapolated from the standard curve and multiplied by the dilution factor. gp120-specific IgG levels were determined by endpoint titration. Twofold serial dilutions of plasma were prepared, starting at a 1:20 dilution. The secondary antibody was an anti-human IgG-HRP (Sigma-Aldrich, USA). Plates were developed and read as described above for IgG. The endpoint IgA titer was defined as the reciprocal of the highest plasma dilution at which the average optical density (OD) value was \( \geq \)2-fold the average OD value for control wells. Sera from HIV-negative subjects were tested as controls.

Depletion of plasma IgA. Bulk IgA was removed from plasma by using the Pierce immuno precipitation kit (Thermo Scientific, USA). Briefly, 1 mg of goat anti-human IgA antibody (Sigma-Aldrich, USA) was immobilized onto columns. Plasma samples diluted 1/10, filtered, heat inactivated, and supplemented with protease inhibitors (Pierce) were added to the columns, incubated overnight at 4°C, and eluted by centrifugation. The flowthrough was collected and stored for further analysis. Plasma samples passed through columns coupled with an isotype-matched control antibody were used as controls (nondepleted plasma). To confirm IgA (but not IgG) depletion, dot blots developed by using either HRP-labeled goat anti-human IgA or IgG antibodies were performed. Additionally, levels of gp120-specific IgA and IgG were quantitated by an ELISA after IgA depletion, as described above for whole plasma. Additionally, IgG binding to gp120-coated cells in IgA-depleted and nondepleted plasma samples was evaluated by flow cytometry using anti-human IgG-APC as a secondary antibody. The mean fluorescence intensity (MFI) was recorded.

Data analysis. Statistical analyses were performed using GraphPad Prism 5 software. Data are expressed as median values with interquartile ranges (25% to 75%) and were analyzed by nonparametric methods unless otherwise stated. Mann-Whitney or Kruskal-Wallis tests were used to compare two or multiple intergroup variables, respectively. A Wilcoxon test was used to compare paired variables. Correlations were determined by using Spearman’s rank test. All tests were considered significant when the \( P \) value was <0.05.

RESULTS

Description of study subjects. Plasma samples from 37 HIV-infected subjects were used: 20 PHI subjects enrolled within 6 months of infection, 10 chronically infected subjects, and 7 ECs (shown in Table 1 and summarized in Table 2). Enrollment samples for PHI subjects were obtained at a median of 60 days from the presumed date of infection and corresponded to Fiebig stages V and VI (31). The median VL and CD4+ T-cell counts for the PHI group at enrollment were 60,335 HIV RNA copies/ml and 16,682 cells/µl, respectively. ECs had undetectable VL and a median of 570 CD4+ T cells/µl. In the PHI group, 5 subjects initiated ART during the first year postinfection (median of 90 days postinfection) following medical indication (Table 1). However, enrollment samples were always obtained before ART instauration. Data obtained by using samples obtained when the subject was on ART were analyzed separately. For certain analyses, PHI subjects were further divided into two subgroups (Tables 1 and 2 and Fig. 1): those whose CD4+ T-cell counts dropped below
FIG 2 ADCC responses in PHI subjects, chronically infected individuals (chronics), and elite controllers (EC) measured by an RFADCC assay. (A) Dot plots for one representative subject per study group. A PKH26-versus-CFSE plot was generated to determine the percentage of ADCC killing, defined as the proportion of cells that remained PKH26[high] but lost the viability dye (CFSE[low]). Percentages shown in each plot correspond to results obtained after calculating and subtracting the background (%ADCC killing for uncoated target cells) from the media of triplicate conditions. Initially, gating was performed with an FSC-versus-SSC plot. Target cells were gated on an SSC-versus-PKH26 plot. (B) Proportion of individuals with the corresponding ADCC titers. To calculate ADCC titers, the threshold for positive responses was defined as the mean background %ADCC killing plus 3 SD. The endpoint ADCC titer was defined as the reciprocal of the higher plasma dilution at which the %ADCC killing was greater than or equal to the threshold. (C)
350 cells/μl at any time during the first year postinfection (PHI<350) (rapid progressors) and those whose CD4+ T-cell counts did not (PHI>350) (typical progressors). By doing this, we aimed to differentiate subjects with more rapid or aggressive progression of early infection and to investigate the association of this pattern with the magnitude of ADCC responses. Regarding chronically infected subjects, the individuals enrolled in this study included subjects with preserved immune status as well as subjects with advanced immune deterioration (Table 1), reflecting the natural heterogeneity of such an HIV-positive (HIV+) population.

**ADCC responses emerge early after infection and increase during the first year postinfection but not in subjects receiving ART.** First, we aimed to revisit previously reported ADCC findings by determining gp120-specific antibodies capable of mediating ADCC in plasma samples from all study subjects (for PHI, enrollment and 12-month samples were used) by using an RFADCC assay. Representative dot plots are shown in Fig. 2A. The results indicated that 80% of PHI subjects had detectable ADCC responses (defined as a titer of ≥1,000) at enrollment, with this number increasing to 100% by 12 months postinfection. Chronically infected subjects had ADCC titers of ≥1,000, and all ECs had titers of ≥10,000 (Fig. 2B). When comparing PHI enrollment and 12-month samples from ART-naive subjects, both the %ADCC killing and ADCC titers significantly increased over time (median %ADCC killing of 12.85% versus 24% [P = 0.0003]; median titer of 1,000 versus 10,000 [P = 0.0206]) (Fig. 2C and D, left). Conversely, subjects who started ART during the course of the study showed a decrease or stability of both ADCC titers and %ADCC killing with the 12-month samples, compared to samples from untreated PHI subjects, chronically infected subjects, and ECs (Fig. 2C and D, right). The %ADCC killing and ADCC titers did not differ significantly between chronically infected and EC subjects. Only a minor, but still significant, difference was observed in comparisons of EC and PHI 12-month ADCC titers.

Overall, gp120-specific antibodies capable of mediating ADCC arise early after infection, and their levels increase over time. This was further noticed when PHI subjects were segregated according to their Fiebig stage at enrollment: samples corresponding to Fiebig stage VI had significantly higher ADCC than did Fiebig stage V samples by analysis of either %ADCC killing (medians of 3.1% and 19.33%, respectively; P = 0.02) or ADCC titers (medians of 1,000 and 10,000, respectively; P = 0.01), thus reinforcing the notion that the magnitude of the ADCC antibody response rapidly increases over time after infection. A plateau is then eventually reached, since no significant difference was observed between PHI 12-month samples and samples from the chronically infected group. Although ECs tended to have higher ADCC than chronically infected individuals, no statistically significant difference was observed, indicating that high titers of ADCC-mediating antibodies are maintained despite the absence of detectable viral replication in standard VL assays (50 HIV RNA copies/ml). The results also illustrated that initiation of ART during the first year postinfection modifies the kinetics of the ADCC response.

**No association between the magnitude of the ADCC response and early disease progression.** We then sought to investigate if the magnitude of the early ADCC response impacts subsequent disease progression. First, ADCC responses in samples from the PHI<350 and PHI>350 groups at both enrollment and 12 months were compared. No significant differences were observed between PHI<350 and PHI>350 groups for either enrollment or 12 month samples (Fig. 2E, left [%ADCC killing]; ADCC titers not shown). No correlations were found between %ADCC killing at enrollment and enrollment VL (Fig. 2E, middle), CD4+ T-cell counts (right), levels of cellular immune activation, or levels of soluble plasma biomarkers of immune activation (not shown). More relevant, no correlations were observed between ADCC at enrollment (evaluated as either %ADCC killing or ADCC titer) and viral set point, immune set point, CD4+ T-cell decay slope, or 12-month VL and CD4+ T-cell counts as alternative markers of disease progression (not shown). Finally, there were no observed correlations between 12-month ADCC and concurrent VL or CD4 T-cell count. Overall, these analyses showed that the magnitude of the early ADCC response has no impact on subsequent disease progression during the time frame investigated.

**HIV-1 Env-specific IgG levels and IgG/IgA ratios (but not IgA levels) correlate with ADCC responses.** Given the lack of observed correlations between ADCC and protection from disease progression, and considering previous reports attributing a protective role to ADCC-mediating antibodies in humans (5, 8, 9), we decided to investigate the presence of putative mitigating factors in the plasma of infected subjects by determining gp120-specific IgG and IgA levels and IgG/IgA ratios in subjects’ plasma samples.

Levels of Env-specific IgG in PHI enrollment samples were significantly lower than those in PHI 12-month samples and in samples from the chronic and EC groups and increased over time in untreated infection but decreased in those subjects that initiated ART (Fig. 3A). No significant difference was observed between PHI 12-month, chronic, and EC samples. Conversely, gp120-specific IgA titers declined over the course of infection except in ECs, who maintained significantly higher gp120-specific IgA titers than those in 12-month PHI and chronic samples (Fig. 3B).

In order to exclude that declining gp120-specific IgA concur-
rent with increasing gp120-specific IgG titers could be an artifact introduced by IgG outcompeting IgA. IgG was depleted in five plasma samples, and gp120-specific IgA was reanalyzed by an ELISA. Identical titers were obtained, excluding the above-mentioned possibility (not shown). IgG/IgA ratios increased over time during PHI, being significantly higher in chronic and in PHI 12-month samples than in PHI enrollment samples (Fig. 3C). No significant difference was observed among 12-month PHI, chronic, and EC samples.

Afterwards, correlations between ADCC and gp120-specific antibodies were studied. For this purpose and since no differences in IgG, IgA, and IgG/IgA ratios between 12-month PHI and chronic samples were observed, data from these groups were merged. To do this, we also took into account that samples from subjects with PHI at 12 months postinfection and from chronically infected subjects did not differ in their virological and immunological parameters (contrary to ECs) (Fig. 1). As reported previously (12, 14, 17, 20), gp120-specific IgG levels directly correlated with ADCC in all study groups ($r = 0.476$ and $P = 0.039$ for PHI enrollment samples [not shown] [shown in Fig. 4A for the rest of the groups]). Conversely, no correlations between gp120-specific IgA and ADCC responses were observed (Fig. 4B). Interestingly, gp120-specific IgG/IgA ratios showed strong direct correlations with ADCC magnitude in the group of 12-month PHI and chronic subjects and in the EC group (Fig. 4C), providing initial support to the notion that gp120-specific IgA antibodies might mitigate the capacity of specific IgG to mediate ADCC.

Depletion of IgA from plasma of viremic HIV-infected subjects enhances the magnitude of ADCC. According to our initial hypothesis, and based on the significant correlations between IgG/IgA ratios and ADCC, we depleted IgA from plasma samples of six randomly selected PHI subjects (12-month samples) and four ECs and reevaluated ADCC responses in both IgA-depleted and non-depleted (passed through an isotype control-coupled column) plasma samples. Figure 5A shows results from one representative PHI subject: IgA was successfully and specifically depleted, as shown by dot blotting (left). In all cases, the gp120-specific IgA titer was <10 after depletion. The ADCC measured in IgA-de-
Compared to nondepleted plasma, the depletion of IgA significantly increased the ADCC response in the plasma from the same subject (Fig. 5A, right). In this specific case, ADCC was negative in nondepleted plasma but became positive after IgA depletion. Moreover, the increment in the magnitude of the ADCC response correlated with a higher level of IgG binding to cells coated with gp120 (Fig. 5, right). This finding was then extended to the other five PHI subjects tested, except for one (Fig. 5B, left). Moreover, IgA depletion did not modify ADCC in ECs (Fig. 5C). In line with this observation, the ADCC ratio of IgA-depleted over nondepleted plasma was significantly higher in subjects with PHI than in ECs (Fig. 5D). Altogether, these results show that plasma IgA modulates ADCC in the context of natural viremic infection, potentially mitigating its protective function.

**ADCC responses in IgA-depleted plasma correlate with the percentage of CD4⁺ T cells.** Finally, correlation analyses between clinical parameters and %ADCC killing observed in IgA-depleted or nondepleted plasma were performed. No correlations were observed between ADCC evaluated in nondepleted plasma and CD4⁺ T-cell percentages (Fig. 6, left). Conversely, a strong, positive, nearly significant correlation between the percentage of CD4⁺ T cells and the magnitude of ADCC obtained with IgA-depleted plasma was found (Fig. 6, right), indicating that eliminating IgA-mediated interference strengthens the association between ADCC and the percentage of CD4⁺ T cells (higher correlation coefficient and also significance (lower P value) of this association. These results, together with those presented above, where higher ADCC values were obtained after IgA removal, indicate that IgA might be interfering with the ADCC mechanism, as measured under our experimental conditions. In turn, this would impede the finding of an association between ADCC and disease progression, which becomes evident after the removal of the IgA component.

**DISCUSSION**

Understanding the role of ADCC-mediating antibodies in the modulation of HIV disease progression is a field of ongoing intense research and renewed interest. In line with the description that vaccine-elicited Env-specific IgA antibodies block gp120 binding of ADCC-mediating IgG (23), evidence of a similar effect occurring in natural viremic HIV infection is...
presented here for the first time. Moreover, ADCC measured in IgA-depleted plasma correlated with CD4^+ T-cell preservation in viremic subjects.

One major achievement of this work was the simultaneous evaluation of ADCC in three groups of HIV-infected subjects at different disease stages (acute versus chronic) and with different clinical outcomes (controlled versus noncontrolled infection). Moreover, clinical follow-up of subjects identified during PHI...
ADCC and IgA in HIV Infection

allowed us to correlate the magnitude of the ADCC response observed at enrollment with subsequent disease progression. We demonstrated that ADCC activity peaks very early after infection, reaches a plateau in chronic infection, and decreases after the instauration of ART, confirming data from previous reports (5–17, 19, 32). The results that we initially obtained using whole plasma supported the notion that ADCC has no beneficial role in slowing disease progression, despite EGs showing slightly higher ADCC than the other groups. This is because no association between ADCC and disease progression (defined by several means) after acute infection in terms of VL, CD4$^+$ T-cell count, soluble factors, and cellular immune activation was found, as shown in Fig. 2. Because results obtained between the PHI>350 and PHI<350 groups were so similar and because the correlations were so weak, we considered that the same results would be obtained even if the sample size was increased. Also, although PHI follow-up was at 1 year, we believe that if ADCC was truly a strong correlate of protection from progression, differences should be observed in the short term after infection, as in the case of cellular immunity (26, 27). The discrepancy between our data and the sizable evidence supporting the idea that ADCC responses could contribute to defense against HIV in the course of natural infection (5, 8, 9) made us reason that it was quite probable that there is a beneficial effect of this effector function in our study but that it is being mitigated by some plasma factors. Thus, we went one step further and provided evidence regarding gp120-specific IgA acting as such a mitigating factor in the context of natural HIV infection, as has been reported in the RV144 vaccine setting (3, 23).

We demonstrate that the level of gp120-specific IgG was associated with the capacity to mediate ADCC in all study groups, which is in agreement with data from previous studies (12, 14, 17, 19, 20), and that there was no correlation between gp120-specific IgA titers and ADCC responses, as also reported previously (12, 14). New to this study is the fact that gp120-specific IgG/IgA ratios are associated with ADCC activity, providing the first evidence of the effect of the IgG/IgA ratio on the magnitude of the ADCC response. One point to consider is that recombinant monomeric gp120 was used in both ADCC analyses and ELISAs. Although a correlation between the magnitude of ADCC and gp120-specific IgG binding in ELISAs was observed here and in other reports, as mentioned above, it is important to note that the gp120 epitopes exposed in each assay differ largely. It has been specifically demonstrated that gp120 epitopes exposed in the RFADCC assay as performed here are those exposed in the gp120 protein after adopting the CD4-bound conformation (33). Moreover, previous reports have shown that exposure of ADCC-specific epitopes in infected cells occurs only after conformational changes associated with CD4 binding occur and were mapped to the gp120 C1 region (34–36). This is particularly relevant in the context of our results: it indicates that antibodies that are able to recognize the gp120 protein bound to CD4 molecules and subsequently trigger ADCC are present in HIV-infected subjects. Thus, therapeutics taking advantage of this mechanism and enhancing this recognition are desirable, as proposed by Richard et al. (37).

Finally, direct evidence of IgA interference in the magnitude of ADCC in natural viremic infection is presented here for the first time, as the level of ADCC measured in IgA-depleted plasma was significantly higher than that in nondepleted plasma for 5 out of 6 subjects. Moreover, ADCC measured in IgA-depleted plasma correlated with CD4$^+$ T-cell preservation. It should be remarked that in the RFADCC assay, NK cells are the effector component (18), and although there are some controversies, it is accepted that NK cells are unable to perform IgA-mediated ADCC (38), highlighting that it is a proper assay to uncover the interfering role of IgA.

The presence of IgA mitigating the protective role of ADCC activity may be a suitable explanation for the discrepancy observed between studies where a correlation of ADCC with protection was reported and others (like ours) where it has been difficult to demonstrate such a correlation. The association of ADCC activity with protection reported previously was achieved by evaluating ADCC responses with the use of purified IgG instead of whole plasma (8, 19). Consequently, the role of the inhibitory effect of IgA in those cases was nonexistent. On the other hand, some early studies reported inhibition of ADCC activity at high plasma concentrations but reported a correlation with disease status using serial dilutions of serum (5, 13). By doing this, the inhibitory factor, in this case IgA, could have been diluted out. Finally, a recent report indicates that the relative ratios of the different IgG subclasses impact ADCC activity during the course of HIV infection. More specifically, the loss of ADCC activity was related to a loss of HIV-specific IgG3 levels and rising titers of subclasses with less functionality (19). Our work adds further evidence to the field demonstrating that IgA interferes with ADCC activity and, therefore, that higher gp120-specific IgG3 levels that are able to counteract the detrimental role of IgA would lead to protective ADCC responses.

Detrimental roles of IgA in other pathologies have also been described (discussed in references 23 and 38). Our results are limited to show that gp120-specific plasma IgA diminishes the magnitude of in vitro IgG-mediated ADCC in viremic HIV$^+$ subjects infected for 1 year, masking its association with the rate of disease progression. What happens in other body compartments, different from plasma, was unexplored, although it deserves consideration.

Finally, a particular picture is observed in ECs: a high magnitude of ADCC despite the absence of significant antigen stimulation, high plasma gp120-specific IgG levels but also high IgA levels, and a positive correlation of the gp120-specific IgG/IgA ratio with ADCC but no IgA interference in depletion experiments. Further insights into IgG and IgA epitope fine-mapping, structure (including glycosylation profiles), function, and affinity in ECs will be needed since dissecting the mechanisms governing HIV-specific IgG and IgA development in ECs, and differences from those in viremic subjects, will be instrumental for developing
strategies to elicit the best humoral immune profile. Specifically, we hypothesize that gp120-specific IgA is directed toward C1 conformational epitopes in subjects where IgA depletion has a considerable impact on ADCC activity (PHI viremic subjects), thus outcompeting C1-specific ADCC-mediating IgG (as reported in the RV144 vaccine setting by Tomaras et al. [23]). On the contrary, in ECs, where IgA depletion has no impact on ADCC activity, IgA specificity may be different from C1, so no IgA-versus-IgG competition occurs. Further investigations in this line will be needed to better understand the basis of ADCC mechanisms in viremic and aviremic subjects.

In summary, we consider that this study represents an important extension beyond the scope of previous reports dealing with ADCC in HIV infection. As initially suggested in the RV144 vaccine setting, gp120-specific IgA antibodies are now identified as factors interfering with the ADCC response in viremic infection, precluding its effect on slowing disease progression. This further emphasizes the notion that vaccine strategies may be more beneficial if they induce IgG-biased antibody responses. Also, much remains to be learned regarding the factors that shape the complex humoral responses in both typical HIV-infected progressors and ECs as well as about the complex interactions between the virus itself and host immunity. As development of an effective vaccine and novel immunotherapies progresses, the data presented here underscore the importance of continuously improving our understanding of the functionality of antibodies elicited either during natural infection or by candidate vaccines.

ACKNOWLEDGMENTS
We thank Florencia Quiroga and Jorge Geffner (Universidad de Buenos Aires–CONICET, Argentina) as well as Andrés Finzi (Université de Montréal, Canada) for critical readings of the manuscript and valuable discussions. Also, we thank Sergio Mazzini and Kevin Madaus for language assistance during manuscript preparation. We are indebted to all the physicians belonging to the Grupo Argentino de Sériconversión Study Group and their patients for their central contributions to this work. Members of the Grupo Argentino de Sériconversión Study Group are Lorena Abusamra, Marcela Acosta, Carolina Acuipil, Viviana Alonso, Liliana Amante, Graciela Ben, M. Belén Bouzas, Ariel Braverman, Mercedes Cabrini, Pedro Cahn, Oswaldo Cando, Cecilia Cánepa, Daniel Cangeboli, Juan Castelli, Mariana Cerioto, Carina Cesar, Maria Collins, Fabio Crudo, Dario Dilemira, Andrea Duarte, Gustavo Echenique, Maria I. Figueroa, Valeria Fink, Claudia Galloso, Palma Granda, Manuel Gómez Carrillo, Ana Gun, Alejandro Krolewiczki, Natalia Laufer, Maire E. Lázaro, Alberto Leoni, Eliana Loiza, Patricia Maldonado, Horacio Mongrone, Marcela Ortiz, Patricia Patterson, Héctor Pérez, Norma Porteiro, Daniel Pryluka, Carlos Remondegui, Raul Román, Horacio Salomón, M. Eugenia Socías, Omar Sued, J. Gonzalo Tomás, Gabriela Turk, Javier Yave, Carlos Zala, and Inés Zapiola.

We have no conflicts of interest to declare.

FUNDING INFORMATION
MINCyT | Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT) and GlaxoSmithKline provided funding to Gabriela Turk under grant number 2011/1658 and 2013/1005. We have no conflicts of interest to declare.

Part of this research was funded by an SNPRC-based grant supported by the Office of Research Infrastructure Programs (OD PSO 0DD1133) to LG. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

REFERENCES
1. Maartens G, Celum C, Lewin SR. 2014. HIV infection: epidemiology, pathogenesis, treatment, and prevention. Lancet 384:258–271. http://dx.doi.org/10.1016/S0140-6736(14)60164-1.
2. Rerks-Ngarm S, Pitisutthitum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DC, Stapleen D, Birch DL, Chunsoontiwat S, Khamboonruang C, Thongcharoop P, Robb ML, Michael NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220. http://dx.doi.org/10.1056/NEJMoa0908492.
3. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karasartsa C, Sutthut R, Liao HX, DeVico AL, Lewis GK, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billinges E, Karasavvas N, Robb ML, Ngyau V, de Souza MS, Paris R, Ferrari G, Baier RT, Soderberg KA, Andrews C, Berman PW, Frahm N, De Rosa SC, Alpert MD, Yates NL, Shen X, Kouk RA, Pittisutthitum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Kim JH. 2012. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275–1286. http://dx.doi.org/10.1056/NEJMoa1113425.
4. Karasartsa C, Paris RM, Cox JH, Nitayaphan S, Pitisutthitum P, Thongcharoop P, Brown M, Gurunathan S, McNeil JG, Birch DL, de Souza MS. 2005. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase II/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23:2522–2529. http://dx.doi.org/10.1016/j.vaccine.2004.10.028.
5. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, Rinaldo C, Del Rio CA, Neehan P, Henrard DR, Phair J. 1996. HIV-1 gp120 specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 157:2168–2173.
6. Chung AW, Navis M, Isitman G, Centre R, Finlayson R, Bloch M, Gerlog L, Kelleher A, Kent SJ, Stratov I. 2011. Activation of NK cells by ADCC responses during early HIV infection. Viral Immunol 24:171–175. http://dx.doi.org/10.1089/vim.2010.0108.
7. Chung AW, Navis M, Isitman G, Wren L, Silvers J, Amin J, Kent SJ, Stratov I. 2011. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 58:127–131. http://dx.doi.org/10.1097/QAI.0b013e31822c62b9.
8. Forthal DN, Landucci G, Daar ES. 2001. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 75:6953–6961. http://dx.doi.org/10.1128/JVI.75.15.6953-6961.2001.
9. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, Haynes BF, Defrajsey IF. 2009. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23:897–906. http://dx.doi.org/10.1097/QAD.0b013e3282929797.
10. Stratov I, Chung A, Kent SJ. 2008. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 82:5450–5459. http://dx.doi.org/10.1128/JVI.01952-07.
11. Thobakgale CF, Fadda L, Lane K, Toth I, Perereya F, Baszer S, Ndung’u T, Walker BD, Rosenberg ES, Alter G, Carrington M, Allen TM, Alfldt M. 2012. Frequent and strong antibody-mediated natural killer cell activation in response to HIV-1 Env in individuals with chronic HIV-1 infection. J Virol 86:6986–6993. http://dx.doi.org/10.1128/JVI.00569-12.
12. Nag P, Kim J, Sapiega V, Landay AL, Bremer JW, Mesteky J, Reichelderfer P, Kovacs A, Cohn J, Weiser B, Baum LL. 2004. Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis 190:1970–1978. http://dx.doi.org/10.1086/425582.
13. Battle-Miller K, Eby CA, Landay AL, Cohen MH, Sha BE, Baum LL. 2002. Antibody-dependent cell-mediated cytotoxicity in cervical lavage fluids of human immunodeficiency virus type 1-infected women. J Infect Dis 185:439–447. http://dx.doi.org/10.1086/338826.
14. Mabuka J, Ndutri R, Odem-Davis K, Peterson D, Overbaugh J. 2012. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 8:e1002739. http://dx.doi.org/10.1371/journal.ppat.1002739.
15. Wren LH, Chung AW, Isitman G, Kelleher AD, Parsons MS, Amin J, Cooper DA, Stratov I, Navis M, Kent SJ. 2013. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunol 138:116–123. http://dx.doi.org/10.1111/imj.12016.

16. Tiemessen CT, Shalekoff S, Meddows-Taylor S, Schramm DB, Papathanasopoulos M, Gray G, Sherman G, Coovadia A, Kuhn L. 2010. Natural killer cells that respond to human immunodeficiency virus type 1 (HIV-1) peptides are associated with control of HIV-1 infection. J Infect Dis 202:1444–1453. http://dx.doi.org/10.1086/656553.

17. Johansson SE, Rollman E, Chung AW, Center RJ, Hejdemann B, Stratov I, Hinjala J, Wahren B, Karre K, Kent SJ, Berg L. 2011. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol 24:359–368. http://dx.doi.org/10.1089/vim.2011.0025.

18. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. 2009. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol 182:1202–1210. http://dx.doi.org/10.4049/jimmunol.182.2.1202.

19. Dugast AS, Stamatatos L, Tonelli A, Suscovich TJ, Licht AF, Mikell I, Wren LH, Chung AW, Isitman G, Kelleher AD, Parsons MS, Amin J, Mota G, Manciulea M, Cosma E, Popescu I, Hirt M, Jensen-Jarolim E, Ljunggren K, Broliden PA, Morfeldt-Manson L, Jondal M, Wahren B, Ghiglione Y, Falivene J, Ruiz MJ, Laufer N, Socias ME, Cahn P, Haynes BF. 2013. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA 110:9019–9024. http://dx.doi.org/10.1073/pnas.1304146110.

20. Mota G, Manciulea M, Cosma E, Popescu I, Hirr M, Jensen-Jarolim E, Calugaru A, Galatuci C, Regalia T, Tamandl D, Spittler A, Boltz-Nitulescu G. 2003. Human NK cells express Fc receptors for IgA which mediate signal transduction and target cell killing. Eur J Immunol 33:2197–2205. http://dx.doi.org/10.1002/eji.200325354.

21. Socías ME, Sued O, Lafer N, Lazaro ME, Mingrone H, Pylrya D, Remondegui C, Figueroa MJ, Cesar C, Gun A, Turk G, Bouzas MB, Kavasery R, Krolewiecki A, Perez H, Salomon H, Cahn P, 2011. Acute retroviral syndrome and high baseline viral load are predictors of rapid HIV progression among untreated Argentinian seroconverters. J Int AIDS Soc 14:40. http://dx.doi.org/10.1186/1758-2652-14-40.

22. Ghiglione Y, Falivene J, Ruiz MJ, Lafer N, Socías ME, Cahn P, Giavedoni L, Sued O, Gherardi MM, Salomon H, Turk G. 2014. Early skewed distribution of total and HIV-specific CD8 T-cell memory phenotypes during primary HIV infection is related to reduced antiviral activity and faster disease progression. PLoS One 9:e104235. http://dx.doi.org/10.1371/journal.pone.0104235.

23. Turk G, Ghiglione Y, Falivene J, Socías ME, Lafer N, Colocciini RS, Rodriguez AG, Ruiz MJ, Pando MA, Giavedoni LD, Cahn P, Sued O, Salomon H, Gherardi MM. 2013. Early Gag immunodominance of the HIV-specific T-cell response during acute/early infection is associated with higher CD8 T-cell antiviral activity and correlates with preservation of the CD4 T-cell compartment. J Virol 87:7415–7426. http://dx.doi.org/10.1128/JVI.00865-13.

24. Giavedoni LD. 2005. Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using Luminex technology. J Immunol Methods 308:53–67. http://dx.doi.org/10.1016/j.jim.2005.09.018.

25. Howell DN, Andreotti PE, Dawson JR, Cresswell P. 1985. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol 134:971–976.

26. Piebg EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada D, Helebrandt C, Smith R, Conrad A, Kleinman SH, Busch MP. 2003. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17:1871–1879. http://dx.doi.org/10.1097/00002030-200309050-00005.

27. Madhavi V, Wren LH, Center RJ, Gonelli C, Winnall WR, Parsons MS, Kramski M, Kent SJ, Stratov I. 2014. Breadth of HIV-1 Env-specific antibody-dependent cellular cytotoxicity: relevance to global HIV vaccine design. AIDS 28:1859–1870. http://dx.doi.org/10.1097/QAD.0b013e3283229607.

28. Richard J, Veillette M, Bataville LA, Coutu M, Chapelle JP, Bonsignori M, Bernard N, Tremblay C, Roger M, Kaufmann DE, Finzi A. 2014. Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. J Virol Methods 208:107–114. http://dx.doi.org/10.1016/j.jviromet.2014.08.003.

29. Veillette M, Desormeaux A, Medjahed H, Gharallah NE, Coutu M, Baalwa J, Guan Y, Lewis G, Ferrari G, Hahn BH, Haynes BF, Robinson JE, Kaufmann DE, Bonsignori M, Sodroski J, Finzi A. 2014. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol 88:2633–2644. http://dx.doi.org/10.1128/JVI.03230-13.

30. Veillette M, Coutu M, Richard J, Bataville LA, Dagoh O, Bernard N, Tremblay C, Kaufmann DE, Roger M, Finzi A. 2015. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol 89:545–551. http://dx.doi.org/10.1128/JVI.02868-14.

31. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, Freel S, Moody MA, Alam SM, Tomaras GD, Ochsenbauer C, Kappes JC, Shaw GM, Hoxie JA, Robinson JE, Haynes BF. 2011. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1-infected individuals. J Virol 85:7029–7036. http://dx.doi.org/10.1128/JVI.00717-11.

32. Richard J, Veillette M, Brassard N, Iyer SS, Roger M, Martin L, Pazgier M, Schon A, Freire E, Routy JP, Smith AB, III, Park J, Jones DM, Courter JR, Melillo BN, Kaufmann DE, Hahn BH, Permar SR, Haynes BF, Madani N, Sodroski JG, Finzi A. 2015. CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci U S A 112:E2678–E2694. http://dx.doi.org/10.1073/pnas.1506755112.

33. Zhou M, Ruprecht RM. 2014. Are anti-HIV IgAs good guys or bad guys? Retrovirology 11:109. http://dx.doi.org/10.1186/s12977-014-0109-5.